Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 684

1.

The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group..

Addiction. 2008 Nov;103(11):1828-36. doi: 10.1111/j.1360-0443.2008.02323.x.

PMID:
18778390
2.

Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.

Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, Spire B.

Clin Infect Dis. 2009 Nov 1;49(9):1433-40. doi: 10.1086/630209.

3.

Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).

Spire B, Lucas GM, Carrieri MP.

Int J Drug Policy. 2007 Aug;18(4):262-70. Review.

PMID:
17689374
4.
5.

Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group.

Carrieri MP, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y.

Drug Alcohol Depend. 2000 Jul 1;60(1):51-4.

PMID:
10821989
6.

Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.

Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS.

Drug Alcohol Depend. 2006 Sep 15;84(2):188-94.

PMID:
16542797
7.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group..

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
8.

Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use.

Stein MD, Rich JD, Maksad J, Chen MH, Hu P, Sobota M, Clarke J.

Am J Drug Alcohol Abuse. 2000 May;26(2):195-205.

PMID:
10852356
9.

Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.

Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP; APROCO cohort study group..

Soc Sci Med. 2002 May;54(10):1481-96.

PMID:
12061483
10.
11.

Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.

Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, Jie S, Mardiati R, Mokri A, Moskalewicz J, Newcombe D, Poznyak V, Subata E, Uchtenhagen A, Utami DS, Vial R, Zhao C.

Addiction. 2008 Sep;103(9):1484-92. doi: 10.1111/j.1360-0443.2008.02249.x.

PMID:
18636999
12.

Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.

Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, Gallant JE.

AIDS. 2001 Sep 7;15(13):1707-15.

PMID:
11546947
13.

Nonadherence among HIV-infected injecting drug users: the impact of social instability.

Bouhnik AD, Chesney M, Carrieri P, Gallais H, Moreau J, Moatti JP, Obadia Y, Spire B; MANIF 2000 Study Group..

J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S149-53.

PMID:
12562040
15.

The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.

Raffa JD, Grebely J, Tossonian H, Wong T, Viljoen M, Khara M, Mead A, McLean M, Duncan F, Petkau AJ, DeVlaming S, Conway B.

Drug Alcohol Depend. 2007 Jul 10;89(2-3):306-9.

PMID:
17383117
16.

Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.

Schaub M, Chtenguelov V, Subata E, Weiler G, Uchtenhagen A.

Int J Drug Policy. 2010 May;21(3):229-33. doi: 10.1016/j.drugpo.2009.10.005.

PMID:
19926271
17.

Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.

Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, Tyndall M, Wood E.

Antivir Ther. 2004 Jun;9(3):407-14.

PMID:
15259903
18.

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group..

J Antimicrob Chemother. 2009 Sep;64(3):599-606. doi: 10.1093/jac/dkp232.

19.

Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).

Carrieri MP, Villes V, Raffi F, Protopopescu C, Preau M, Salmon D, Taieb A, Lang JM, Verdon R, Chene G, Spire B; APROCO-COPILOTE ANRS CO-08 Study Group..

Int J Drug Policy. 2007 Aug;18(4):288-95.

PMID:
17689377
20.

Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users.

Clarke S, Delamere S, McCullough L, Hopkins S, Bergin C, Mulcahy F.

HIV Med. 2003 Jan;4(1):33-7.

Items per page

Supplemental Content

Support Center